Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis

Inflammatory Bowel Diseases

Volumn 21, Issue 5, 2015, Pages 1089-1097

  Allegretti, Jessica R ^a   Barnes, Edward L ^a   Cameron, Anna ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

cervical cancer; high grade cervical dysplasia; immunosuppression; inflammatory bowel disease

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID;

ARTICLE; CANCER RISK; CERVICAL HIGH GRADE DYSPLASIA; COHORT ANALYSIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; NEWCASTLE OTTAWA SCORE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; CANCER GRADING; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; IMMUNOCOMPROMISED PATIENT; INFLAMMATORY BOWEL DISEASES; PATHOLOGY; PROGNOSIS; RISK FACTOR; UTERINE CERVIX CARCINOMA IN SITU;

CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; NEOPLASM GRADING; PROGNOSIS; RISK FACTORS;

EID: 84929072705     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000338     Document Type: Article

References (30)

1. Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007;26:987-1003.
2. Cutrell J, Bedimo R. Non-AIDS-defining cancers among HIV-infected patients. Curr HIV/AIDS Rep. 2013;10:207-216.
3. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-Term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351:623-628.
4. Gallagher MP, Kelly PJ, Jardine M, et al. Long-Term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol. 2010;21:852-858.
5. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-Term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177-186.
6. Kalil AC, Florescu MC, Grant W, et al. Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-Analysis. Expert Rev Anti Infect Ther. 2014;12:881-896.
7. Miro JM, Aguero F, Duclos-Vallee JC, et al. Infections in solid organ transplant HIV-infected patients. Clin Microbiol Infect. 2014;20 (Suppl 7):119-130.
8. Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS. 2014;28:453-465.
9. Shahapur PR, Bidri RC. Recent trends in the spectrum of opportunistic infections in human immunodeficiency virus infected individuals on antiretroviral therapy in South India. J Nat Sci Biol Med. 2014;5:392-396.
10. Wang CC, Silverberg MJ, Abrams DI. Non-AIDS-Defining malignancies in the HIV-infected population. Curr Infect Dis Rep. 2014;16:406.
11. Neparidze N, Lacy J. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. Clin Adv Hematol Oncol. 2014;12:358-371.
12. Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol. 2011;51:103-108.
13. Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol. 2007;25:2975-2982.
14. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIVinfected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009;58:1-166.
15. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516-542.
16. Velayos F. Managing risks of neoplasia in inflammatory bowel disease. Curr Gastroenterol Rep. 2012;14:174-180.
17. Rungoe C, Simonsen J, Riis L, et al. Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study. Clin Gastroenterol Hepatol. 2015;13:693-700.
18. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91: 854-862.
19. Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-To-severe Crohn's disease. Am J Gastroenterol. 2009;104:2524-2533.
20. Kim SC, Glynn RJ, Giovannucci E, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. [published online ahead of print March 11, 2014]. DOI: 10.1136/annrheumdis-2013-204993.
21. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006; 12:6167-6171.
22. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103: 631-636.
23. Lees CW, Critchley J, Chee N, et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis. 2009; 15:1621-1629.
24. Hutfless S, Fireman B, Kane S, et al. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:598-605.
25. Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested casecontrol study. Gastroenterology. 2009;136:451-458.
26. Busnach G, Piselli P, Arbustini E, et al. Immunosuppression and cancer: a comparison of risks in recipients of organ transplants and in HIVpositive individuals. Transpl Proc. 2006;38:3533-3535.
27. Greywoode R, LaFond J, Fine S, et al. Women with inflammatory bowel disease do not receive adequate cervical cancer screening or pregnancy counseling. Inflamm Bowel Dis. 2013;19:E6-E7.
28. Mahadevan U. Cervical neoplasia risk in IBD: truth or hysteria?. Inflamm Bowel Dis. 2009;15:1619-1620.
29. Zabana Y, Barreiro M, Manosa M, et al. Cervical dysplasia in immunosuppressed IBD women. Inflamm Bowel Dis. 2009;15:1774.
30. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res. 2005;11:4717-4723.